Evidence map›Paper›PMID 41872169›Full record

ArticleNature communications2026

RNA functional modulation by Mitoxantrone via RNA structural ensemble repartitioning.

Chundan Zhang, Ivana Borovská, Teona Iobashvili, Edoardo Morandi, Marta Lionnez, Oluwatosin S Olayinka, Rinse de Boer, Massimiliano Clamer, Martin D Witte, Klaus Pors and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chundan Zhang *Department of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute (GBB), University of Groningen, Groningen, the Netherlands.
Ivana Borovská *Department of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute (GBB), University of Groningen, Groningen, the Netherlands.ORCID http://orcid.org/0000-0002-8090-387X
Teona IobashviliDepartment of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute (GBB), University of Groningen, Groningen, the Netherlands.ORCID http://orcid.org/0009-0004-2686-5560
Edoardo MorandiDepartment of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute (GBB), University of Groningen, Groningen, the Netherlands.
Marta LionnezStratingh Institute for Chemistry, University of Groningen, Groningen, the Netherlands.
Oluwatosin S OlayinkaInstitute of Cancer Therapeutics, Faculty of Health and Social Care, University of Bradford, Bradford, UK.
Rinse de BoerDepartment of Molecular Immunology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, the Netherlands.
Massimiliano ClamerIMMAGINA Biotechnology S.r.l., Viale dell'Industria 47, Pergine Valsugana (TN), Italy.
Martin D WitteStratingh Institute for Chemistry, University of Groningen, Groningen, the Netherlands.ORCID http://orcid.org/0000-0003-4660-2974
Klaus PorsInstitute of Cancer Therapeutics, Faculty of Health and Social Care, University of Bradford, Bradford, UK.
John S SchneeklothChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Danny IncarnatoDepartment of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute (GBB), University of Groningen, Groningen, the Netherlands. d.incarnato@rug.nl.ORCID http://orcid.org/0000-0003-3944-2327

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeting RNA with small molecules offers a strategy to modulate gene expression at undruggable targets. Traditional screens favor thermodynamically stable, low-entropy RNA motifs with defined conformations, yet these provide limited energetic leverage for functional modulation. Many RNAs instead sample dynamic structural ensembles that small molecules can repartition. Using group I self-splicing introns as a model, we identified the antineoplastic drug Mitoxantrone as a competitive inhibitor of RNA self-splicing (IC

Indexed as

Antineoplastic AgentsMitoxantroneRNA5' Untranslated RegionsHumansIntronsNucleic Acid ConformationRNA SplicingStructure-Activity Relationship5' Untranslated RegionsAntineoplastic AgentsMitoxantroneRNA

Identifiers

PMID41872169
PMCPMC13172499

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.